1.Relationship of Oxidative Stress in Hepatitis B Infection Activity with HBV DNA and Fibrosis.
Fazilet DUYGU ; Hasan KARSEN ; Nurten AKSOY ; Abdullah TASKIN
Annals of Laboratory Medicine 2012;32(2):113-118
BACKGROUND: The aim of this study was to evaluate oxidative stress in various clinical forms of hepatitis B infection and to investigate its role in the development of the chronic form of the disease. METHODS: Ninety-three patients with inactive hepatitis B surface antigen (HbsAg) carrier state (IHBCS), 65 patients with chronic hepatitis B infection (CHB), and 42 healthy adults were included in the study. The following values were measured and compared in patient groups: total antioxidant status (TAS), total oxidative stress (TOS), oxidative stress index (OSI), sulfhydryl (SH), lipid peroxidation (LOOH), catalase (CAT), and ceruloplasmin. In patients with chronic hepatitis B, these values were compared with HBV DNA and fibrosis levels. RESULTS: ALT, TOS, LOOH, and OSI levels were higher in the CHB group compared to the other groups (P<0.001). Catalase levels increased in the CHB and IHBCS groups compared to the control group (P<0.001). Total aminooxidant and ceruloplasmin levels were found to be lowest in the CHB group and highest in the control group (P<0.001). Sulfhyrdyl was higher in the control group compared to the other groups (P<0.001). In the CHB group, there was no correlation between the HBV DNA and OSI (P>0.05). CONCLUSIONS: These finding suggested that oxidative stress is associated with hepatitis B activity.
Adolescent
;
Adult
;
Aged
;
Alanine Transaminase/blood
;
Antioxidants/metabolism
;
Carrier State
;
Catalase/blood
;
DNA, Viral/*analysis
;
Female
;
Fibrosis
;
Hepatitis B/*metabolism/pathology
;
Hepatitis B Surface Antigens/blood
;
Hepatitis B virus/*genetics
;
Hepatitis B, Chronic/metabolism/pathology
;
Humans
;
Lipid Peroxidation
;
Male
;
Middle Aged
;
*Oxidative Stress
;
Sulfhydryl Compounds/blood
;
Young Adult
2.COVID-19 vaccine candidates and vaccine development platforms available worldwide
Duman NILGUN ; ALzaidi ZAHRAA ; Aynekin BUSRA ; Taskin DUYGU ; Demirors BUSRA ; Yildirim ABDULBAKI ; Sahin Olcay IZEM ; Bilgili FAIK ; Turanli Tahir EDA ; Beccari TOMMASO ; Bertelli MATTEO ; Dundar MUNIS
Journal of Pharmaceutical Analysis 2021;11(6):675-682
The pandemic caused by the worldwide spread of the coronavirus,which first appeared in 2019,has been named coronavirus disease 19 (COVID-19).More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),according to the World Health Organization.COVID-19 Dashboard in September 2021.Apart from the wildtype,other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020.Modifications in the SARS-CoV-2 genetic material,such as mutation and recombi-nation,have the ability to modify the viral life span,along with transitivity,cellular tropism,and symptom severity.Several processes are involved in introducing novel vaccines to the population,including vaccine manufacturing,preclinical studies,Food and Drug Administration permission or cer-tification,processing,and marketing.COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies,such as RNA,DNA,protein,and viral vectored vaccines.This comprehensive review,which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality,was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development.